BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33002893)

  • 1. Genomic Study of Chinese Quadruple-negative GISTs Using Next-generation Sequencing Technology.
    Wang S; Sun RZ; Han Q; Wang SY; Wang EH; Liu Y
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):34-41. PubMed ID: 33002893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.
    Gasparotto D; Rossi S; Polano M; Tamborini E; Lorenzetto E; Sbaraglia M; Mondello A; Massani M; Lamon S; Bracci R; Mandolesi A; Frate E; Stanzial F; Agaj J; Mazzoleni G; Pilotti S; Gronchi A; Dei Tos AP; Maestro R
    Clin Cancer Res; 2017 Jan; 23(1):273-282. PubMed ID: 27390349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST.
    Urbini M; Astolfi A; Indio V; Nannini M; Schipani A; Bacalini MG; Angelini S; Ravegnini G; Calice G; Del Gaudio M; Secchiero P; Ulivi P; Gruppioni E; Pantaleo MA
    Sci Rep; 2020 Nov; 10(1):19829. PubMed ID: 33199729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
    Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinicopathological features of KIT/PDGFRA wild-type gastrointestinal stromal tumors.
    Nishida T; Naito Y; Takahashi T; Saito T; Hisamori S; Manaka D; Ogawa K; Hirota S; Ichikawa H
    Cancer Sci; 2024 Mar; 115(3):894-904. PubMed ID: 38178783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation.
    Miettinen M; Killian JK; Wang ZF; Lasota J; Lau C; Jones L; Walker R; Pineda M; Zhu YJ; Kim SY; Helman L; Meltzer P
    Am J Surg Pathol; 2013 Feb; 37(2):234-40. PubMed ID: 23282968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
    Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
    Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.
    Brenca M; Rossi S; Polano M; Gasparotto D; Zanatta L; Racanelli D; Valori L; Lamon S; Dei Tos AP; Maestro R
    J Pathol; 2016 Mar; 238(4):543-9. PubMed ID: 26606880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated?
    Jašek K; Váňová B; Grendár M; Štanclová A; Szépe P; Hornáková A; Holubeková V; Plank L; Lasabová Z
    Pathol Res Pract; 2020 Nov; 216(11):153171. PubMed ID: 32836055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).
    Nannini M; Astolfi A; Urbini M; Indio V; Santini D; Heinrich MC; Corless CL; Ceccarelli C; Saponara M; Mandrioli A; Lolli C; Ercolani G; Brandi G; Biasco G; Pantaleo MA
    BMC Cancer; 2014 Sep; 14():685. PubMed ID: 25239601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.
    Ricci R; Martini M; Ravegnini G; Cenci T; Milione M; Lanza P; Pierconti F; Santini D; Angelini S; Biondi A; Rosa F; Alfieri S; Clemente G; Persiani R; Cassano A; Pantaleo MA; Larocca LM
    Clin Epigenetics; 2019 Jan; 11(1):2. PubMed ID: 30616628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways.
    Pantaleo MA; Nannini M; Corless CL; Heinrich MC
    Cancer Med; 2015 Jan; 4(1):101-3. PubMed ID: 25165019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing.
    Hechtman JF; Zehir A; Mitchell T; Borsu L; Singer S; Tap W; Oultache A; Ladanyi M; Nafa K
    Genes Chromosomes Cancer; 2015 Mar; 54(3):177-84. PubMed ID: 25427437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age.
    Miettinen M; Wang ZF; Sarlomo-Rikala M; Osuch C; Rutkowski P; Lasota J
    Am J Surg Pathol; 2011 Nov; 35(11):1712-21. PubMed ID: 21997692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].
    Kalfusová A; Kodet R
    Cesk Patol; 2017; 53(4):167-173. PubMed ID: 29227120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
    Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
    Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
    Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
    J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
    Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.